Agonist
Back to library
GH SecretagogueSubcutaneous

CJC-1295 (no DAC)

Also known as: Modified GRF 1-29 · Mod GRF 1-29 · MGRF · CJC no-DAC

Tetrasubstituted GHRH(1-29) analog without the drug affinity complex (DAC) linker. Triggers a short, physiologic GH pulse from the pituitary. Often paired with a ghrelin mimetic for synergistic release.

At a glance

Half-life
30 minutes
Common route
Subcutaneous
Typical dose range
100–200mcg
Stability (reconstituted)
30days refrigerated

Best timing

Fasted. 1–3x daily, typically paired with ipamorelin in the same syringe. Pre-bed dose aligns with natural GH peak.

Contraindications

  • Active cancer
  • Severe insulin resistance
  • Pregnancy
  • Diabetic retinopathy

Watch symptoms

  • Facial flushing for 5–15 minutes post-injection
  • Head pressure or headache
  • Lightheadedness
  • Injection site numbness
  • Increased dream vividness when dosed at night

Citations

The primary literature.

  1. 01Short-term safety of CJC-1295, a long-acting human growth hormone-releasing hormone (GHRH) analogPubMed
  2. 02Effects of growth hormone-releasing hormone analog (CJC-1295) on growth hormone and insulin-like growth factor IPubMed

Related protocols

Stacks that use CJC-1295 (no DAC).

Sleep & Recovery Stack

Pre-bed GH-pulse stack for deeper sleep and overnight recovery.

View protocol
Back to library